Surprised there been no comments around this collab considering it sounds to be a product with similar mode of action to Cellpryme
immuno-oncology company Imugene and NeoImmuneTech, a T-cell-focused biopharmaceutical company based in Maryland, USA, have come together to evaluate Imugene’s allogeneic CAR T azer-cel in combination with NeoImmuneTech’s proprietary immune T-cell amplifier NT-I7 for the treatment of cancer.Combined, the two treatments are expected to lead to an increase in the number and cancer-fighting properties of a patient’s own T-cells during their treatment with azer-cel.NeoImmuneTech’s NT-I7 is the only long-acting human interleukin-7 (IL-7) cytokine in clinical stage development and has been found to play a key role in T-cell development and survival, boosting cancer fighting T-cell numbers, their health and functionality to enhance immune function and potentially provide improved cancer fighting benefits to patients.
Surprised there been no comments around this collab considering...
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.002(4.65%) |
Mkt cap ! $33.01M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.0¢ | $63.85K | 1.572M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 136111 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 183918 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
4.1¢ |
Change
-0.002 ( 4.65 %) |
||||
| Open | High | Low | Volume | ||
| 4.1¢ | 4.2¢ | 4.0¢ | 819958 | ||
| Last updated 15.50pm 17/06/2024 ? | |||||
| PTX (ASX) Chart |
